These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31107640)

  • 21. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
    Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
    Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
    Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
    Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of human papillomavirus vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Markowitz LE
    Emerg Infect Dis; 2008 Feb; 14(2):244-51. PubMed ID: 18258117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
    Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
    Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States.
    Laprise JF; Chesson HW; Markowitz LE; Drolet M; Martin D; Bénard É; Brisson M
    Ann Intern Med; 2020 Jan; 172(1):22-29. PubMed ID: 31816629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
    Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
    Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review.
    Favato G; Easton T; Vecchiato R; Noikokyris E
    Vaccine; 2017 May; 35(20):2622-2632. PubMed ID: 28408119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
    Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
    Van Minh H; My NTT; Jit M
    BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
    Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.
    Ekwunife OI; Lhachimi SK
    BMC Health Serv Res; 2017 Dec; 17(1):815. PubMed ID: 29216880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.